申请人:Delta Pharmaceuticals, Inc.
公开号:US05574159A1
公开(公告)日:1996-11-12
Diarylmethyl piperazine compounds having utility as exogenous receptor combinant species for binding with receptors such as delta, mu, sigma, and/or kappa receptors are disclosed. Compounds of the invention may be employed as conjugates in agonist/antagonist pairs for transductional monitoring and assays of neurotransmitter function, and also variously exhibit therapeutic utility, including mediating analgesia, and possessing utility for the treatment of diarrhea, urinary incontinence, mental illness, drug and alcohol addiction/overdose, lung edema, depression, asthma, emphysema, cough, and apnea, respiratory depression, cognitive disorders, emesis and gastrointestinal disorders.
本发明揭示了具有外源性受体结合物种功能的二芳甲基哌嗪化合物,用于与δ、μ、σ和/或κ受体结合。本发明的化合物可作为激动剂/拮抗剂对中的共轭物,在神经递质功能的传导监测和检测中使用,并且也具有各种治疗效用,包括介导镇痛,并具有治疗腹泻、尿失禁、精神疾病、药物和酒精成瘾/过量、肺水肿、抑郁症、哮喘、肺气肿、咳嗽和呼吸暂停、呼吸抑制、认知障碍、呕吐和胃肠疾病的功效。